Venn Life Sciences has joined the Irish Stock Exchange’s (ISE) Enterprise Securities Market (ESM), utilising the ESM’s dual listing regime with the London Stock Exchange’s AIM to enable Irish and international investors access their shares through a euro-denominated quotation.
With a market capitalisation of €19m, Venn Life Sciences provides drug development, clinical trial management and resourcing solutions to pharmaceutical, biotechnology and medical device organisations.
The company has operations in France, Germany, the Netherlands, UK and Ireland and also has resources across the globe working on clinical studies.
Deirdre Somers, CEO, Irish Stock Exchange, said: “We are delighted to welcome Venn Life Sciences to our equity market. Venn Life Sciences is an ambitious company with significant plans to expand throughout Europe. It is great to see another company in the pharmaceutical and biotechnology sector choosing to list on the ISE.”
Venn Life Science CEO Tony Richardson added: “Joining the Enterprise Securities Market was an easy decision for us. Given our existing listing on AIM, the process to add an ESM quotation was very straightforward. Having a euro quotation through the ISE will enable us to expand our investor base by accessing both euro and sterling pools of capital and facilitate future growth.”